Literature DB >> 9818755

Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.

M Cuenca-Estrella1, J L Rodríguez-Tudela, E Mellado, J V Martínez-Suárez, A Monzón.   

Abstract

Voriconazole was compared with amphotericin B and itraconazole by a modification of the NCCLS microdilution reference method for yeasts against 62 clinical isolates of Aspergillus fumigatus. MICs of voriconazole were slightly lower than those of amphotericin B and itraconazole. The MIC of voriconazole at which 90% of isolates were inhibited was 1 mg/L and the MIC range was 0.25-2 mg/L. Voriconazole is a new antifungal agent with potential for use in the treatment of A. fumigatus infections.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9818755     DOI: 10.1093/jac/42.4.531

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  30 in total

Review 1.  Voriconazole: in the treatment of invasive aspergillosis.

Authors:  Richard B R Muijsers; Karen L Goa; Lesley J Scott
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers.

Authors:  Lynn Purkins; Nolan Wood; Parviz Ghahramani; Diane Kleinermans; Gary Layton; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

3.  The pharmacokinetics of voriconazole.

Authors:  Atholl Johnston
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

4.  Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen.

Authors:  Ville-Veikko Hynninen; Klaus T Olkkola; Kari Leino; Stefan Lundgren; Pertti J Neuvonen; Anders Rane; Mika Valtonen; Hanna Vyyryläinen; Kari Laine
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis.

Authors:  W R Kirkpatrick; R K McAtee; A W Fothergill; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

6.  Efficacy of voriconazole in treatment of murine pulmonary blastomycosis.

Authors:  A M Sugar; X P Liu
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

7.  A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.

Authors:  E Mellado; G Garcia-Effron; L Alcázar-Fuoli; W J G Melchers; P E Verweij; M Cuenca-Estrella; J L Rodríguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

8.  Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.

Authors:  Claudia Michael; Uta Bierbach; Katrin Frenzel; Thoralf Lange; Nadezda Basara; Dietger Niederwieser; Christine Mauz-Körholz; Rainer Preiss
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

9.  Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.

Authors:  Ping Liu; Grover Foster; Robert Labadie; Eugene Somoza; Amarnath Sharma
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

10.  In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp.

Authors:  Alicia Gomez-Lopez; Guillermo Garcia-Effron; Emilia Mellado; Araceli Monzon; Juan L Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.